Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 22, No 16 (August 15), 2004: pp. 3420-3428
© 2004 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2004.02.019

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mehlen, P.
Right arrow Articles by Fearon, E. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mehlen, P.
Right arrow Articles by Fearon, E. R.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

BIOLOGY OF NEOPLASIA

Role of the Dependence Receptor DCC in Colorectal Cancer Pathogenesis

Patrick Mehlen, Eric R. Fearon

From the Apoptosis/Differentiation Laboratory, Equipe labelisée ‘La Ligue’ Molecular and Cellular Genetic Center, University of Lyon, Villeurbanne; International Agency For Research in Cancer, Lyon, France; and Division of Molecular Medicine & Genetics, University of Michigan Medical Center, Ann Arbor, MI

Address reprint requests to P. Mehlen, MD, Apoptosis/Differentiation Laboratory–Molecular and Cellular Genetic Center, CNRS UMR 5534, University of Lyon, 69622 Villeurbanne, France; e-mail: mehlen{at}univ-lyon1.fr

More than a decade ago, the DCC (deleted in colorectal cancer) gene was proposed as a putative tumor suppressor gene. Data supporting this proposal included observations that one DCC allele was deleted in roughly 70% of colorectal cancers, some cancers had somatic mutations of the DCC gene, and DCC expression was often reduced or absent in colorectal cancer tissues and cell lines. Despite subsequent studies which have supported DCC's potential role as a tumor suppressor gene, the rarity of point mutations identified in DCC coding sequences, the lack of a tumor predisposition phenotype in mice heterozygous for DCC inactivating mutations, and the presence of other known and candidate tumor suppressor genes on chromosome 18q have raised questions about DCC's candidacy. Following its initial characterization, the DCC protein was identified as a transmembrane receptor for netrins, key factors in axon guidance in the developing nervous system. At first glance, the established role of DCC and netrin-1 during organization of the spinal cord could be viewed as a further challenge to the position that DCC inactivation might play a significant role in tumorigenesis. However, recent observations on DCC's functions in intracellular signaling have renewed interest in the potential contribution of DCC inactivation to cancer. In particular, data indicate that, when engaged by netrin ligands, DCC may activate downstream signaling pathways. Moreover, in settings where netrin is absent or at low levels, DCC can promote apoptosis. Here, we review DCC's candidacy as a tumor suppressor gene, with an emphasis on how recent molecular analyses of DCC have offered support for the notion that DCC may function as a tumor suppressor gene.

Authors' disclosures of potential conflicts of interest are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
CarcinogenesisHome page
S. Derks, L. J.W. Bosch, H. E.C. Niessen, P. T.M. Moerkerk, S. M. van den Bosch, B. Carvalho, S. Mongera, J.W. Voncken, G. A. Meijer, A. P. de Bruine, et al.
Promoter CpG island hypermethylation- and H3K9me3 and H3K27me3-mediated epigenetic silencing targets the deleted in colon cancer (DCC) gene in colorectal carcinogenesis without affecting neighboring genes on chromosomal region 18q21
Carcinogenesis, June 1, 2009; 30(6): 1041 - 1048.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
C. Delloye-Bourgeois, E. Brambilla, M.-M. Coissieux, C. Guenebeaud, R. Pedeux, V. Firlej, F. Cabon, C. Brambilla, P. Mehlen, and A. Bernet
Interference With Netrin-1 and Tumor Cell Death in Non-Small Cell Lung Cancer
J Natl Cancer Inst, February 18, 2009; 101(4): 237 - 247.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. Furne, N. Rama, V. Corset, A. Chedotal, and P. Mehlen
Netrin-1 is a survival factor during commissural neuron navigation
PNAS, September 23, 2008; 105(38): 14465 - 14470.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
D. Goldschneider, N. Rama, C. Guix, and P. Mehlen
The Neogenin Intracellular Domain Regulates Gene Transcription via Nuclear Translocation
Mol. Cell. Biol., June 15, 2008; 28(12): 4068 - 4079.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
J. Fitamant, C. Guenebeaud, M.-M. Coissieux, C. Guix, I. Treilleux, J.-Y. Scoazec, T. Bachelot, A. Bernet, and P. Mehlen
Netrin-1 expression confers a selective advantage for tumor cell survival in metastatic breast cancer
PNAS, March 25, 2008; 105(12): 4850 - 4855.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. L. Carvalho, A. Chuang, W.-W. Jiang, J. Lee, S. Begum, L. Poeta, M. Zhao, C. Jeronimo, R. Henrique, C. S. Nayak, et al.
Deleted in Colorectal Cancer Is a Putative Conditional Tumor-Suppressor Gene Inactivated by Promoter Hypermethylation in Head and Neck Squamous Cell Carcinoma
Cancer Res., October 1, 2006; 66(19): 9401 - 9407.
[Abstract] [Full Text] [PDF]


Home page
Phil Trans R Soc BHome page
B. K Mueller, T. Yamashita, G. Schaffar, and R. Mueller
The role of repulsive guidance molecules in the embryonic and adult vertebrate central nervous system
Phil Trans R Soc B, September 29, 2006; 361(1473): 1513 - 1529.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. J. Raz, B. He, R. Rosell, and D. M. Jablons
Current concepts in bronchioloalveolar carcinoma biology.
Clin. Cancer Res., June 15, 2006; 12(12): 3698 - 3704.
[Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
C. Furne, V. Corset, Z. Herincs, N. Cahuzac, A.-O. Hueber, and P. Mehlen
The dependence receptor DCC requires lipid raft localization for cell death signaling.
PNAS, March 14, 2006; 103(11): 4128 - 4133.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
W. Li, J. Aurandt, C. Jurgensen, Y. Rao, and K.-L. Guan
FAK and Src kinases are required for netrin-induced tyrosine phosphorylation of UNC5
J. Cell Sci., January 1, 2006; 119(1): 47 - 55.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
Z. Herincs, V. Corset, N. Cahuzac, C. Furne, V. Castellani, A.-O. Hueber, and P. Mehlen
DCC association with lipid rafts is required for netrin-1-mediated axon guidance
J. Cell Sci., April 15, 2005; 118(8): 1687 - 1692.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2004 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online